References
- Montefusco V, Gay F, Spina F, Miceli R, Maniezzo M, Ambrosini MT, Farina L, Piva S, Palumbo A, Boccadoro M, Corradini P. Antibiotic prophylaxis before dental procedures may reduce the incidence of osteonecrosis of the jaw in multiple myeloma patients treated with bisphosphonates. Leuk Lymphoma 2008;49:2156–2162
- Koka S, Clarke B L, Amin S, Gertz M, Ruggiero S L. Oral bisphosphonate therapy and osteonecrosis of the jaw: what to tell the concerned patient. Int J Prosthodont 2007; 20: 115–122
- Russell R G. Bisphosphonates: from bench to bedside. Ann NY Acad Sci 2006; 1068: 367–401
- Lambrinoudaki I, Christodoulakos G, Botsis D. Bisphosphonates. Ann NY Acad Sci 2006; 1092: 397–402
- Hess L M, Jeter J M, Benham-Hutchins M, Alberts D S. Factors associated with osteonecrosis of the jaw among bisphosphonate users. Am J Med 2008; 121: 475–483.e3
- Berenson J R, Lichtenstein A, Porter L, Dimopoulos M A, Bordoni R, George S, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med 1996; 334: 488–493, Comment in: N Engl J Med 1996;334:529–530
- Barri Y M, Munshi N C, Sukumalchantra S, Abulezz S R, Bonsib S M, Wallach J, et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int 2004; 65: 634–641
- Durie B G, Katz M, Crowley J. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353: 99–102, discussion 99–102
- Dimopoulos M A, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos L A, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006; 91: 968–971
- Lacy M Q, Dispenzieri A, Gertz M A, Greipp P R, Gollbach K L, Hayman S R, et al. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006;81:1047–1053; Comment in: Mayo Clin Proc 2007;82(4):516–517; author reply 517–518. Mayo Clin Proc 2007; 82(1)134, author reply 134–135
- Kyle R A, Yee G C, Somerfield M R, Flynn P J, Halabi S, Jagannath S, et al. American society of clinical oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 2007; 25: 2464–2472
- Cafro A M. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: definition and management of the risk related to zoledronic acid. Clin Lymphoma Myeloma 2008; 8: 111–116